GlassScriptPhysician profile
Bella Aloyts
NPI 1750451407
$15,485.86
in general payments reported to CMS, 2019-2025
37 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,145 · 2020: $1,471 · 2021: $1,965 · 2022: $2,543 · 2023: $2,863 · 2024: $2,865 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,362.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,259.83 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $2,292.31 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,903.80 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,203.65 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $712.19 | 2021-2025 | |
| Novo Nordisk INC | $642.16 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $617.52 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $544.08 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $521.93 | 2019-2023 | Mounjaro, Jardiance |
| Aimmune Therapeutics, INC. | $403.70 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $387.99 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $341.30 | 2021-2024 | Linzess |
| Amarin Pharma, INC. | $317.80 | 2019-2022 | |
| Allergan, INC. | $268.17 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $239.11 | 2020-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bella Aloyts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.